2023 Cancer Genetics and Epigenetics GRC & GRS

2023 癌症遗传学和表观遗传学 GRC

• 批准号: 10683603
• 负责人: Ting Wang
• 金额: $ 1.6万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-17 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10683603
• 关键词: 3-Dimensional; Address; Biological Assay; CRISPR screen; Cancer Control; Cells; Chromatin; Chromatin Structure; Clustered Regularly Interspaced Short Palindromic Repeats; Collaborations; Complement; Computer Analysis; Computing Methodologies; DNA Transposable Elements; Data; Development; Emerging Technologies; Engineering; Epigenetic Process; Future Generations; Gene Expression; Gene Expression Profile; Gene Expression Regulation; Genetic; Genetic Heterogeneity; Genome; Genomics; Goals; Immune response; Immunotherapy; Individual; Inter-tumoral heterogeneity; Knowledge; Lead; Learning; Malignant Neoplasms; Modernization; Molecular; Mutation; Pathway interactions; Play; Precision therapeutics; Predisposition; RNA; Research; Research Personnel; Role; Sampling; Scientist; Surveys; Systems Analysis; Tail; Technology; Tumor Biology; Untranslated RNA; Work; cancer diagnosis; cancer genetics; cancer genome; cancer genomics; cancer heterogeneity; cancer therapy; design; driver mutation; drug discovery; epigenetic therapy; epigenome; epitranscriptome; experimental study; genome-wide; genomic data; inhibitor; insight; meetings; novel; novel therapeutic intervention; posters; precision oncology; single cell technology; symposium; targeted treatment; tool; tumor

SUMMARY The 2023 Conference on Cancer Genetics and Epigenetics will highlight the new development, challenges and opportunities in precision cancer medicine. The conference will focus on emerging technologies and analytical computational methods deciphering mechanistic insights from the studies of individual cancer genome and epigenome leading to drug discoveries and novel precision therapeutics. Heterogeneity of cancer and evolutionary trajectory of cancer will be explored in the context of genetics, epigenetics as well as genome topology, enabled by modern technologies including single cell genomics and CRISPR-based genome and epigenome engineering tools amenable to studies in tumor samples. An emphasis will be put on the emerging roles of non-coding genome and epi-transcriptome in cancer, and how they inform novel therapeutic strategies. Challenges in designing future generation cancer genomics studies and integrating large cancer genomics data will be addressed. This meeting should appeal to a wide range of cancer researchers, molecular biologists, and bioinformaticians seeking to apply the latest genetics and epigenetics discoveries to their work to cancer. In addition to an outstanding set of invited speakers there will be several interactive poster sessions, one minute "poster preview" talks and several talks selected for platform presentation from the submitted abstracts.

总结 2023年癌症遗传学和表观遗传学会议将突出新的发展，挑战和 精准癌症医疗的机会。会议将重点关注新兴技术和分析 计算方法从个体癌症基因组的研究中破译机械的见解， 表观基因组导致药物发现和新的精确疗法。癌症的异质性， 癌症的进化轨迹将在遗传学、表观遗传学和基因组学的背景下进行探索。 拓扑结构，由现代技术实现，包括单细胞基因组学和基于CRISPR的基因组， 适用于肿瘤样本研究的表观基因组工程工具。重点将放在新兴的 非编码基因组和表观转录组在癌症中的作用，以及它们如何为新的治疗策略提供信息。 设计下一代癌症基因组学研究和整合大型癌症基因组学数据的挑战 将得到解决。这次会议应该吸引广泛的癌症研究人员，分子生物学家， 生物信息学家寻求将最新的遗传学和表观遗传学发现应用到他们的癌症工作中。在 除了一组杰出的受邀演讲者外，还将有几个互动海报会议，一分钟 “海报预览”讲座和从提交的摘要中选出的几个讲座。